Introduction:Schizophrenia is a chronic mental disorder characterized by a range of cognitive, behavioral, and emotional dysfunctions. This study compares the efficacy and tolerability of Haloperidol and Aripiprazole, two antipsychotics used in its treatment.Material and method: the study was Conducted at the Department of Psychiatry, Guru Gobind Singh Medical College and Hospital, Faridkot, the study involved 50 drug-naïve patients aged 18-65, who met the ICD-11 criteria for schizophrenia. Patients were divided into two groups, one receiving Haloperidol (5-15 mg/day) and the other Aripiprazole (5-20 mg/day). The efficacy of the treatments was evaluated using the Positive and Negative Syndrome Scale (PANSS) at baseline and at follow-ups at 2, 6, and 12 weeks. Tolerability was assessed by monitoring adverse drug reactions and extrapyramidal symptoms (EPS) using the Modified Simpson Angus Scale (MSAS).Results indicated that both Haloperidol and Aripiprazole significantly improved PANSS scores over time, with no statistically significant differences between the two groups across all time points. However, Aripiprazole showed a trend towards greater improvement in Negative symptoms, though not reaching statistical significance. In terms of tolerability, both medications were comparable, though Aripiprazole's atypical profile may offer advantages in long-term treatment adherence. Conclusion:These findings suggest that both Haloperidol and Aripiprazole are effective in treating schizophrenia, with Aripiprazole potentially offering a slightly better outcome in managing Negative symptoms and adherence. The study underscores the importance of individualized treatment approaches in optimizing care for schizophrenia patients.